Corrigendum: Development and Validation of Nomogram Models for Predicting Immune-Related Adverse Events in Recurrent and Metastatic Nasopharyngeal Carcinoma Patients Treated with PD-L1 Inhibitors

Mengyuan Liu¹Zheran Liu^2*Shuangshuang He³Yiyan Pei²Shihong Xu²Junyou Ge⁴Yan Qing⁴Youneng Wei⁴Ye Chen^5*Ping Ai^3*Xingchen Peng^2*

• ¹West China Hospital, Sichuan University, Chengdu, China
• ²Department of Targeting Therapy & Immunology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
• ³Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
• ⁴Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, Sichuan Province, China
• ⁵Division of Abdominal Tumor Multimodality Treatment, Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China

In The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.1.In the published article, there was an error in Table 1 as published. In the ECOG performance status row, the current version displays the numerical coding used for statistical modeling (i.e., 1 and 2). This should be revised to reflect the actual clinical values (ECOG = 0 and ECOG = 1), as presented to clinicians. This is a purely representational change and does not affect any statistical analyses. The corrected Table 1 and its caption Baseline characteristics of patients with and without immune-related adverse events (irAEs) appear below. 2.In the published article, there was an error in Table 2 as published. A portion of the fatiguerelated data was inadvertently omitted during table compilation. Upon verification, the total number of fatigue events, including Grade 1-2, should be 4. Please note that the number of patients with or without irAEs remains unchanged, and all related analyses remain valid. The corrected Table2 and its caption Incidence and severity of immune-related adverse events (irAEs) among patients appear below. 3. In the published article, there was an error in Figure 4 as published. After publication, we realized that the survival curve presented in Figure 4 overlaps with data previously published by Dr. Shihong Xu in Oral Oncology (2025; https://doi.org/10.1016/j.oraloncology.2024.107161).Dr. Xu is one of our research collaborators. Although using the same database, we analysed different markers. We focused on the predictive modeling. We acknowledge that including this